Results 171 to 180 of about 3,251,164 (295)

SOME REMARKS ON THE EXHIBITION OF OXYGEN AS A THERAPEUTIC, [PDF]

Samuel Birch
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Multimodal Key Anti-Oncolytic Therapeutics Are Effective In Cancer Treatment? [PDF]

Int J Nanomedicine
Ye L, Gao M, Chen Y, Zhu Y, Wang J, Wang Z.   +5 more
europepmc   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Twenty years of therapeutic development in tauopathy mouse models: a scoping review. [PDF]

Alzheimers Dement
Langness VF, Simmons DA, McHugh TLM, Butler RR, Zhou J, Liu H, Yang T, Ellerby LM, Longo FM.   +8 more
europepmc   +1 more source

Therapeutic Results in Treatment of Hodgkin’s Disease with CB 1348 and R-48 [PDF]

, 1957
Antonio Rottino
openalex   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Impact of therapeutic hypothermia on cardiogenic shock outcomes: a systematic review and meta-analysis. [PDF]

Ann Intensive Care
Cherbi M, Levy B, Gautier P, Aissaoui N, Guinot PG, Merdji H, Delmas C.   +6 more
europepmc   +1 more source

Hospital Experiments on the Supposed Therapeutical Action of the Excreta of Serpents [PDF]

Richard Payne Cotton
openalex   +1 more source

Therapeutic Hemapheresis [PDF]

Transfusion Medicine and Hemotherapy, 2012
Mansouri Taleghani, Behrouz, Strasser, Erwin   +1 more
openaire   +4 more sources